A late stage clinical trial of the experimental drug colchicine for secondary prevention of cardiovascular events has been halted after interim analysis showed no benefit over placebo. The failure of the drug, which targets inflammation, has cast doubt on the long standing theory that inflammation plays a causal role in heart disease progression. Researchers are now re evaluating the inflammatory hypothesis of atherosclerosis, a cornerstone of cardiovascular medicine for decades.
The phase 3 trial, known as COLCOT 2, was designed to test whether low dose colchicine could reduce the risk of recurrent heart attacks, strokes, or cardiovascular death in patients who had already experienced a cardiovascular event. The drug, an anti inflammatory medication commonly used for gout and pericarditis, was expected to demonstrate benefits by suppressing chronic inflammation linked to atherosclerosis.
However, an independent data monitoring committee reviewed interim results and recommended stopping the trial early due to a lack of efficacy. The final analysis confirmed that colchicine did not significantly reduce the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, or urgent hospitalization for angina compared to placebo. The findings were presented at the European Society of Cardiology Congress and simultaneously published in the *New England Journal of Medicine*.
DISCUSSION (0)